Alan H.  Auerbach net worth and biography

Alan Auerbach Biography and Net Worth

Alan H. Auerbach has served as our Chairman of the Board and as our Chief Executive Officer and President since our inception. Prior to founding Puma, Mr. Auerbach served as Founder, Chief Executive Officer, President and a Member of the Board of Directors of Cougar Biotechnology, Inc., from the company's inception in 2003 until its acquisition by Johnson & Johnson in July 2009.

From July 2009 until January 2010, Mr. Auerbach served as Co-Chairman of the Integration Steering Committee at Cougar (as part of Johnson & Johnson) that provided leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate. Abiraterone was approved for the treatment of metastatic prostate cancer in the U.S. in April 2011 and in the European Union in September 2011.

Prior to founding Cougar, from June 1998 to April 2003 Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle- capitalization biotechnology companies, with a focus on companies in the field of oncology. He had primary responsibility for technical, scientific and clinical due diligence, as well as selection of biotechnology companies followed by the company. During 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small-capitalization biotechnology companies. Prior to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology.

Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California.

What is Alan H. Auerbach's net worth?

The estimated net worth of Alan H. Auerbach is at least $32.33 million as of January 3rd, 2024. Mr. Auerbach owns 6,936,947 shares of Puma Biotechnology stock worth more than $32,326,173 as of March 19th. This net worth approximation does not reflect any other assets that Mr. Auerbach may own. Additionally, Mr. Auerbach receives an annual salary of $1,740,000.00 as CEO at Puma Biotechnology. Learn More about Alan H. Auerbach's net worth.

How old is Alan H. Auerbach?

Mr. Auerbach is currently 54 years old. There are 4 older executives and no younger executives at Puma Biotechnology. Learn More on Alan H. Auerbach's age.

What is Alan H. Auerbach's salary?

As the CEO of Puma Biotechnology, Inc., Mr. Auerbach earns $1,740,000.00 per year. Learn More on Alan H. Auerbach's salary.

How do I contact Alan H. Auerbach?

The corporate mailing address for Mr. Auerbach and other Puma Biotechnology executives is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. Puma Biotechnology can also be reached via phone at (424) 248-6500 and via email at [email protected]. Learn More on Alan H. Auerbach's contact information.

Has Alan H. Auerbach been buying or selling shares of Puma Biotechnology?

During the last ninety days, Alan H. Auerbach has sold $185,868.04 of Puma Biotechnology stock. Most recently, Alan H. Auerbach sold 41,396 shares of the business's stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $4.49, for a transaction totalling $185,868.04. Following the completion of the sale, the chief executive officer now directly owns 6,936,947 shares of the company's stock, valued at $31,146,892.03. Learn More on Alan H. Auerbach's trading history.

Who are Puma Biotechnology's active insiders?

Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Douglas Hunt (Insider), Ann Miller (Director), Maximo Nougues (CFO), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.

Are insiders buying or selling shares of Puma Biotechnology?

During the last year, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 199,396 shares worth more than $728,295.40. The most recent insider tranaction occured on January, 3rd when insider Alvin F Wong sold 7,733 shares worth more than $34,721.17. Insiders at Puma Biotechnology own 22.7% of the company. Learn More about insider trades at Puma Biotechnology.

Information on this page was last updated on 1/3/2024.

Alan H. Auerbach Insider Trading History at Puma Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2024Sell41,396$4.49$185,868.046,936,947View SEC Filing Icon  
7/3/2023Sell60,698$3.31$200,910.386,978,343View SEC Filing Icon  
1/3/2023Sell27,241$4.18$113,867.386,852,638View SEC Filing Icon  
11/2/2022Sell1,242$2.25$2,794.506,312,949View SEC Filing Icon  
10/3/2022Sell1,260$2.34$2,948.406,314,191View SEC Filing Icon  
8/2/2022Sell1,247$2.89$3,603.836,316,705View SEC Filing Icon  
7/5/2022Sell26,140$2.63$68,748.206,317,952View SEC Filing Icon  
6/2/2022Sell1,200$1.94$2,328.006,344,092View SEC Filing Icon  
5/3/2022Sell1,263$2.32$2,930.166,345,292View SEC Filing Icon  
4/4/2022Sell1,198$3.08$3,689.846,346,555View SEC Filing Icon  
3/2/2022Sell1,294$2.26$2,924.44View SEC Filing Icon  
2/2/2022Sell1,316$2.46$3,237.36View SEC Filing Icon  
1/3/2022Sell22,875$3.19$72,971.25View SEC Filing Icon  
12/2/2021Sell1,837$2.90$5,327.30View SEC Filing Icon  
11/2/2021Sell1,795$5.63$10,105.85View SEC Filing Icon  
10/4/2021Sell1,858$6.15$11,426.70View SEC Filing Icon  
9/2/2021Sell1,764$7.60$13,406.404,417,790View SEC Filing Icon  
8/2/2021Sell1,764$7.53$13,282.92View SEC Filing Icon  
7/2/2021Sell5,332$8.84$47,134.88View SEC Filing Icon  
6/2/2021Sell1,757$10.74$18,870.184,426,650View SEC Filing Icon  
5/3/2021Sell1,758$9.01$15,839.584,428,407View SEC Filing Icon  
4/5/2021Sell1,584$9.80$15,523.204,430,165View SEC Filing Icon  
1/4/2021Sell18,235$10.22$186,361.704,284,258View SEC Filing Icon  
12/2/2020Sell355$11.66$4,139.304,302,493View SEC Filing Icon  
11/2/2020Sell371$7.82$2,901.224,302,848View SEC Filing Icon  
10/2/2020Sell350$10.13$3,545.504,303,219View SEC Filing Icon  
9/2/2020Sell347$9.78$3,393.664,303,569View SEC Filing Icon  
7/2/2020Sell2,607$10.66$27,790.624,304,246View SEC Filing Icon  
5/4/2020Sell339$9.70$3,288.304,307,195View SEC Filing Icon  
4/2/2020Sell347$7.39$2,564.334,307,534View SEC Filing Icon  
2/3/2020Sell331$8.01$2,651.314,180,700View SEC Filing Icon  
12/2/2019Sell455$10.33$4,700.154,187,047View SEC Filing Icon  
11/4/2019Sell478$7.40$3,537.204,187,602View SEC Filing Icon  
10/2/2019Sell504$9.97$5,024.884,187,980View SEC Filing Icon  
9/4/2019Sell524$10.14$5,313.364,188,484View SEC Filing Icon  
8/2/2019Sell517$9.03$4,668.5136,812View SEC Filing Icon  
7/22/2019Sell12,715$9.98$126,895.704,189,525View SEC Filing Icon  
7/2/2019Sell495$12.78$6,326.104,202,240View SEC Filing Icon  
6/3/2019Sell483$15.18$7,331.944,202,735View SEC Filing Icon  
5/2/2019Sell477$32.38$15,445.264,203,218View SEC Filing Icon  
4/2/2019Sell491$35.79$17,572.894,203,695View SEC Filing Icon  
3/4/2019Sell496$38.62$19,155.524,204,186View SEC Filing Icon  
2/4/2019Sell345$27.80$9,591.004,165,467View SEC Filing Icon  
1/22/2019Sell8,825$24.74$218,330.504,165,812View SEC Filing Icon  
1/3/2019Sell4,424$20.67$91,444.0831,333View SEC Filing Icon  
7/20/2018Sell12,520$52.00$651,040.004,179,061View SEC Filing Icon  
1/22/2018Sell10,692$92.75$991,683.004,155,931View SEC Filing Icon  
7/20/2017Sell13,175$94.73$1,248,067.754,170,623View SEC Filing Icon  
1/20/2017Sell10,202$33.24$339,114.484,179,798View SEC Filing Icon  
See Full Table

Alan H. Auerbach Buying and Selling Activity at Puma Biotechnology

This chart shows Alan H Auerbach's buying and selling at Puma Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Puma Biotechnology Company Overview

Puma Biotechnology logo
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $4.66
Low: $4.48
High: $5.00

50 Day Range

MA: $5.52
Low: $4.56
High: $7.40

2 Week Range

Now: $4.66
Low: $2.13
High: $7.73

Volume

1,294,484 shs

Average Volume

701,267 shs

Market Capitalization

$224.66 million

P/E Ratio

10.13

Dividend Yield

N/A

Beta

1.32